CVS Caremark (CVS), a drugstore chain that competes with Rite-Aid Corporation (RAD), Walgreen Company (WAG), and Wal-Mart Stores, Inc. (WMT), is acting in a boring way this afternoon. My screen shows, at the time of this writing, the stock down 44 cents, or 1.2%, to $36.64.

That's not too bad for the kind of trading session we're having. I bet CVS would have been up today following its Q1 report had the market action been different. But the tape is the tape, you can do nothing about that. According to Bloomberg BusinessWeek, the company made, on an adjusted basis, 60 cents per share, which was two pennies ahead of estimates.

Continue reading Does CVS Look Okay After Q1 Report?

Does CVS Look Okay After Q1 Report? originally appeared on BloggingStocks on Tue, 04 May 2010 18:00:00 EST. Please see our terms for use of feeds.

Rite Aid (RAD) continues to be a stock that I want to avoid. I know it's risen a lot over the last year, but such price action doesn't sway me in this case.

You've got to be careful when a company reports a loss, even if that loss is narrower than what was reported in the comparable period. In the fiscal fourth quarter, Rite Aid lost 24 cents per share. Last year at this time, the red ink came out to $2.67 per share. Yes, this is a vast improvement; same thing happened in the third quarter back in December of last year.

Continue reading Rite Aid Down on Q4 Report

Rite Aid Down on Q4 Report originally appeared on BloggingStocks on Wed, 31 Mar 2010 18:30:00 EST. Please see our terms for use of feeds.

Walgreen Company (WAG), a drugstore entity whose major competitors are CVS Caremark (CVS), Rite Aid (RAD), and Wal-Mart Stores, Inc. (WMT), reported second-quarter data earlier today; they weren't too thrilling, to be completely honest.

On a reported basis, net income increased three pennies to 68 cents per share. On an adjusted basis, earnings came out to 70 cents per share (this would be after adding back the two pennies dedicated to restructuring charges). Estimates called for 71 cents per share. Poor Walgreen just couldn't keep up with the analysts this time around.

Continue reading Walgreen Company Reports a Not-So-Compelling Second Quarter

Walgreen Company Reports a Not-So-Compelling Second Quarter originally appeared on BloggingStocks on Tue, 23 Mar 2010 16:20:00 EST. Please see our terms for use of feeds.

CVS Caremark (CVS), which competes with Walgreen (WAG), Rite Aid (RAD), and Wal-Mart (WMT), posted fourth-quarter data on Monday. Sales increased 7%, and adjusted earnings per share from continuing operations (excluding, in addition, a penny per share relating to a tax benefit) came in at 78 cents -- good for a growth rate of over 11%. That bottom-line performance matched analyst projections, according to our earnings preview.

As we all know, matching expectations is sometimes the death of a stock. The market has no conscience when it comes to mercilessly punishing an equity for not going beyond the call of the analysts. However, CVS actually did pretty well yesterday, rising 5% by the end of the session; the move was backed by healthy volume.

Continue reading CVS Caremark: Long-Term Bet After Q4?

CVS Caremark: Long-Term Bet After Q4? originally appeared on BloggingStocks on Tue, 09 Feb 2010 08:30:00 EST. Please see our terms for use of feeds.

Walgreen (WAG), a drugstore chain that competes with CVS Caremark (CVS) and Rite Aid (RAD), issued fiscal Q1 numbers on Monday. The growth rates were impressive.

Total sales were up 9.5%. Net income increased almost 20% to 49 cents per diluted share. Operational cash flow was higher by over three times. According to our earnings preview, analysts were expecting 48 cents per share. Of course, since there were restructuring charges included in the above per-share profit stat (equal to 3 cents per share), the beat is better than it looks. This was indeed a good quarter.

Continue reading Walgreen Achieves Impressive Growth in Q1

Walgreen Achieves Impressive Growth in Q1 originally appeared on BloggingStocks on Tue, 22 Dec 2009 17:30:00 EST. Please see our terms for use of feeds.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Adobe Systems Inc. (ADBE) shares rose after lower Q4 earnings and revenue beat analysts' expectations.
• Best Buy Inc. (BBY) shares sold off despite better-than-expected Q3 results due to the lower gross margin.
• Charles Schwab Corp. (SCHW) warned that Q4 earnings would come in lower than the Street view
• Discover Financial Services (DFS) shares were up after it reported better-than-expected Q4 earnings.
• First Solar Inc. (FSLR) offered a solid 2010 outlook but the consensus EPS estimate is high in the range.
• General Mills Inc. (GIS) strong Q2 results included better-than-expected earnings and a rosy outlook.

Continue reading Earnings highlights: Best Buy, Discover, General Mills, Nike, Oracle, Rite Aid, Take-Two ...

Earnings highlights: Best Buy, Discover, General Mills, Nike, Oracle, Rite Aid, Take-Two ... originally appeared on BloggingStocks on Sat, 19 Dec 2009 11:40:00 EST. Please see our terms for use of feeds.

According to this summary at Reuters, top-line sales decreased a little under 2%, and the loss per share came in at 10 cents. This was a lot better than the 30 cents per share lost in the comparable quarter. Expectations were for the red ink to be closer to 18 cents per share.

Continue reading Rite Aid Defeats Analysts in Q3, but Investors Should Be Careful

Rite Aid Defeats Analysts in Q3, but Investors Should Be Careful originally appeared on BloggingStocks on Fri, 18 Dec 2009 16:30:00 EST. Please see our terms for use of feeds.

Rite Aid Corp. (NYSE: RAD) wallowed in the red Thursday morning, after the drugstore chain disappointed Wall Street with its second-quarter earnings and full-year guidance.

Rite Aid said its quarterly loss narrowed to $116 million, or 14 cents per share, while revenue dwindled 2.7% to $6.3 billion. Same-store sales dipped 1.1%, while gross margin contracted from 27.4% to 26.7%.

Continue reading Rite Aid plunges after slashing full-year outlook

Rite Aid plunges after slashing full-year outlook originally appeared on BloggingStocks on Thu, 24 Sep 2009 11:40:00 EST. Please see our terms for use of feeds.

Rite Aid (NYSE: RAD), which competes with Walgreen (NYSE: WAG), CVS Caremark (NYSE: CVS), and Wal-Mart (NYSE: WMT), saw a big increase in volume on Wednesday after it reported earnings for the first quarter. In fact, as Douglas McIntyre observed, shares of Rite Aid were up 5% at one point during yesterday's session. However, the shares ended up losing their green status by the close of trading. Rite Aid actually lost 3% when all was said and done. What does it all mean?

Well, Rite Aid did beat analyst forecasts by a wide margin. The call was for a loss of 13 cents per share. Rite Aid lost only 6 cents per share once adjustments are made. Revenues dipped a little over 1%, and same-store sales, after excluding the effect of the Brooks Eckerd acquisition, increased 1.5%. Interestingly, the mix of this increase is as follows: the pharmacy sales went up 3.1% on a comparable basis, and the non-pharmacy sales went down 1.4% on the same basis.

Continue reading Rite Aid beats analysts, but not right for me yet

Rite Aid beats analysts, but not right for me yet originally appeared on BloggingStocks on Thu, 25 Jun 2009 09:00:00 EST. Please see our terms for use of feeds.

Rite Aid (NYSE: RAD), whose competitors include Walgreen (NYSE: WAG), CVS Caremark (NYSE: CVS), and Wal-Mart (NYSE: WMT), reported Q4 numbers today, and when you read through the release, you sort of come away with a decent feeling. You hear about improvements in this metric and that metric. You wonder if a turnaround might be in the offing. Then you look at the stock price and, even though it is currently being bid higher (it's up over 14% as I write), you come back down to earth and reality hits you in the face. Anything trading under a buck has to give you pause. Rite Aid is no different.

For the quarter, Rite Aid posted a 1.7% decrease in the top line. On an adjusted basis, the drugstore chain reported a loss of $0.14 per share. According to this source, Wall Street thought Rite Aid might lose $0.105 per share. The company is still adjusting to the Brooks Eckerd acquisition. Excluding that effect, same-store sales increased 0.8%. Including the asset, comps decreased 0.1%.

Continue reading Rite Aid up on Q4 report -- can you buy it now?

Rite Aid up on Q4 report -- can you buy it now? originally appeared on BloggingStocks on Thu, 02 Apr 2009 15:10:00 EST. Please see our terms for use of feeds.

Walgreen (NYSE: WAG), a drugstore chain which competes with CVS Caremark (NYSE: CVS) and Rite Aid (NYSE: RAD), dropped the ball in the fourth quarter, at least as far as analyst estimates are concerned. On a GAAP basis, Walgreen increased its earnings per share by a nickel, coming in at 45 cents.

That would be pretty cool if there were no adjustments to be made. Unfortunately, there is one. It relates to an adjustment for vacation-time accrual, which added almost $80 million to the bottom line. Take that away, and you get no earnings growth, as earnings per share would have been 40 cents, meaning non-GAAP number missed expectations by 5 cents.

I think Walgreen is a strong brand in its space. However, with the economic meltdown continuing its dire course, I would imagine that the chain is going to become affected by it, strong brand or not. Drug prescriptions certainly might be considered a defensive element in such an environment, but keep in mind that Walgreen doesn't just make its money on prescription sales. It sells a whole host of items in every location. And I'd have to imagine that the consumer is going to be scaling back. Yep, get ready for the good ole negative wealth effect.

Continue reading Walgreen stumbles in Q4

Walgreen stumbles in Q4 originally appeared on BloggingStocks on Tue, 30 Sep 2008 09:45:00 EST. Please see our terms for use of feeds.

Rite Aid (NYSE: RAD), a drugstore brand that competes with Walgreen (NYSE: WAG) and CVS Caremark (NYSE: CVS), reported results for the second quarter on Thursday. Unfortunately, they did not meet the expectations of analysts. Revenues were basically flat at $6.5 billion. The net loss more than doubled to $0.27 per diluted share, compared to $0.10 per diluted share one year ago. According to this item, Wall Street was hoping that Rite Aid might be able to deliver a loss of $0.15 per diluted share. Furthermore, that news source states that guidance for the fiscal year is worse than the consensus. The consensus believed that Rite Aid might bleed about $0.51 per share in red ink. The loss will at least be $0.56 per share, according to management. It might even go as high as $0.67.

So, I just gave out all the nasty stuff. Is there anything encouraging from the release? Let me put on my look-on-the-bright-side glasses. Net cash from operations was positive during the quarter. Over $96 million was generated. Last year, operations required almost $140 million. I dig cash, no doubt about it. But I really love free cash flow. If you add back sale-leaseback transactions, there was some free cash, but I can't say it changes my general stance on Rite Aid. I mean, overall same-store sales are weak, and the stock is currently priced at less than a buck. It's done horribly year-to-date according to the AOL Finance snapshot taken at the time of this writing. Down 67%. Not encouraging.

Rite Aid's shares aren't so much stock certificates as they are lottery tickets. Do you like playing the lottery? If so, go buy one of those scratch-off deals. You might have better luck with them than you would with Rite Aid.

Disclosure: I don't own any company mentioned; positions can change at any time.

Rite Aid disappoints investors in Q2 originally appeared on BloggingStocks on Fri, 26 Sep 2008 10:45:00 EST. Please see our terms for use of feeds.

My primary mission was to acquire some toothpaste, but there are always a few tempting sale items. When I was checking out I discovered that the sports drink for sale at "5 for $5 dollars" was a mistake and the sign in the store display should have been taken down because the offer had expired. Another item I purchased was marked down from $3.99 to $1.99, great deal! . . . but they told me that the sale price was placed on the wrong shelf for that product and what I wanted was not on sale.

Continue reading Rite Aid (RAD) is wrong, wrong, wrong!

Rite Aid (RAD) is wrong, wrong, wrong! originally appeared on BloggingStocks on Wed, 02 Jul 2008 14:43:00 EST. Please see our terms for use of feeds.

CVS Caremark

Looking through the reported growth rates, you can see that we're talking best-of-breed here. Revenues were up over 60%, and adjusted earnings per share increased over 18%, coming in at $0.55. The Caremark merger has obviously proven to be a good move. Same-store sales rose 3.9%, benefited in part by the early appearance of Easter in March.

According to earnings.com, CVS Caremark basically matched earnings expectations. That's okay, though, I don't think you can hold it against this big brand name. As of this writing, CVS is near a 52-week high. Buying at the 52-week high is always a dicey thing, but if you plan on holding for years, it wouldn't be that much of a concern. Shorter-term traders would need to wait for a pullback. But I like the first quarter results for CVS, and I think the stock is poised to do well over time. And like I said at the beginning, this really may be a stock for the core portion of an individual's investment program -- a true buy-and-hold idea.

Disclosure: I don't own shares in any company mentioned here; positions can change at any time.

CVS: Is the company core-portfolio material? originally appeared on BloggingStocks on Mon, 05 May 2008 15:35:00 EST. Please see our terms for use of feeds.

Continue reading Rite Aid (RAD) swings to loss in fourth-quarter

Rite Aid (RAD) swings to loss in fourth-quarter originally appeared on BloggingStocks on Thu, 10 Apr 2008 11:17:00 EST. Please see our terms for use of feeds.

Rite Aid (NYSE: RAD), I should disclose, is one of my least favorite companies and stocks. Nevertheless, I don't mind checking in on it from time to time when there is news about it. Yesterday, the pharmacy released sales data for the month of March (the data excludes the Brooks Eckerd acquisition). Did they change my outlook on Rite Aid at all?

No, although I should say that this wouldn't be necessarily expected; a month of same-store sales data isn't the killer app of an overall investment thesis for a retail idea. Still, shareholders follow comps religiously, and I have to say that Rite Aid's number was nothing to write home about. A 2.6% gain in sales at stores open more than a year is weak. Walgreen (NYSE: WAG) said earlier in the week that its comparable-store revenues grew by a much better 4.4%. Walgreen was able to take advantage of the Easter shopping excitement in a much better fashion than Rite Aid. It all comes down to brand and execution; Walgreen, as well as CVS Caremark (NYSE: CVS), are more valuable in terms of both those attributes.

I may not have been bowled over by Walgreen's recent earnings release, but I can tell you that Rite Aid's share price is downright frightening and telling -- it's telling people to stay away, or at least understand that it may be essentially like buying a lottery ticket (it closed at $2.89 yesterday). Rite Aid's same-store sales were weak, and so is its investment potential.

Disclosure: I don't own shares in any of the companies mentioned here; positions can change at any time.

Rite Aid's comps are no panacea for stock price originally appeared on BloggingStocks on Fri, 04 Apr 2008 14:23:00 EST. Please see our terms for use of feeds.

Walgreen Company (NYSE: WAG) reported earnings for the second quarter on Monday. Net sales grew by a very decent 10%. Diluted earnings per share for the quarter were $0.69 versus $0.65 in the year-ago period; this represents a bottom-line gain of 6%.

Considering some of the other action on Wall Street on Monday -- the increased offer for Bear Stearns, the approval of the Sirius/XM merger -- Walgreen's earnings report was simply an okay event, even though the stock closed up around 5% on the news. Same-store sales may have increased 4.7%, but the retailer sold a lot of items with lower margins this time around, thus reducing its gross-margin metric by 14 basis points (the release did cite a big shift to pharmacy sales in the quarter as having negatively impacted margins). So Walgreen needs to work on its non-pharmacy revenues. One cool thing from the report is the jump in net cash from operations -- that number increased by 10%.

Walgreen, which competes with CVS Caremark Corporation (NYSE: CVS) and Rite Aid Corporation (NYSE: RAD), isn't a bad way to play the long-term drug-retailing business. To be sure, baby boomers -- as well as everyone else -- will always need to visit drugstores on a go-forward basis. It's the company that can capture a significant amount of non-pharmacy sales that will prosper the most. Walgreen and CVS are excellent brand names in this sector -- I'm not so keen on Rite Aid, though (take a look at the stock price and see if you think the company might be cheap-for-a-reason, as they say).

Disclosure: I don't own any shares in any of the companies mentioned here; positions can change at any time.

Walgreen's earnings were an 'okay event' originally appeared on BloggingStocks on Mon, 24 Mar 2008 17:41:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Oppenheimer upgraded shares of Teradyne Inc (NYSE: TER) to Outperform from Perform after channel checks indicated several positive catalysts, including continued market share gains and that the company is benefiting from the inventory build of game consoles.
  
• Jefferies upgraded Omnivision Technologies (NASDAQ: OVTI) to Buy from Hold and named the stock their Tuesday Value Pick, as they find the risk/reward favorable at current levels. Jefferies thinks fundamentals will likely bottom in the April quarter.
• JMP Securities raised DemandTec Inc (NASDAQ: DMAN) to Strong Buy from Outperform, as they believe the company had a very strong close to the year and is seeing real traction with its Promotions product.

• MasterCard Incorporated (NYSE: MA) was raised to Neutral from Outperform at Credit Suisse.
  
• JP Morgan upgraded Rite Aid Corporation (NYSE: RAD) and Campbell Soup Company (NYSE: CPB) to Overweight from Neutral.
  
• Bear raised Repsol SA (NYSE: REP) to Outperform from Peer Perform.

Analyst upgrades: MA, RAD, CPB, TER, OVTI and DMAN originally appeared on BloggingStocks on Tue, 26 Feb 2008 10:53:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Societe Generale upgraded shares of Sanofi-Aventis (NYSE: SNY) to Buy from Hold as they believe pipeline maturation over the next 12 months can drive the stock higher.
  
• Piper upgraded shares of Lifecell (NASDAQ: LIFC) to Outperform from Market Perform after their recent survey indicated that AlloDerm remains the leading biologic hernia mesh on the market and competition is making little headway.
  
• JP Morgan upgraded Mylan Labs (NYSE: MYL), Panera Bread (NASDAQ: PNRA) and Norsk Hydro (NYSE: NHY) to Overweight from Neutral. The firm upgraded Mylan based on its position in the global generics market and above-average growth; Panera was upgraded on valuation, as they believe the recent operating risk is now behind the company; Norsk Hydro was upgraded, as they believe the value of the company's aluminum assets are higher than the current share price suggests.

• HSBC upgraded Ride Aid (NYSE: RAD) to Neutral from Underweight.
  
• UBS upgraded Standard Pacific (NYSE: SPF) and Ciena (NASDAQ: CIEN) to Neutral from Sell and Sherwin-Williams (NYSE: SHW) to Buy from Neutral.
  
• Goldman added Cytec Industries (NYSE: CYT) to its Conviction Buy List.

Analyst upgrades: SNY, LIFC, MYL, PNRA and NHY originally appeared on BloggingStocks on Thu, 04 Oct 2007 10:45:00 EST. Please see our terms for use of feeds.

Rite Aid

Continue reading Rite Aid (RAD) reports increased second-quarter loss

Rite Aid (RAD) reports increased second-quarter loss originally appeared on BloggingStocks on Thu, 27 Sep 2007 17:45:00 EST. Please see our terms for use of feeds.